Effects of the central analgesic tramadol on the uptake and release of noradrenaline and dopamine in vitro.

1. The centrally acting analgesic, tramadol, has low affinity for opioid receptors and therefore presumably other mechanisms of analgesic action. Neurotransmitter release and uptake experiments were used to characterize the effects of tramadol on the central noradrenergic and dopaminergic systems.

Additional myocardial salvage by coadministration of the epoprostenol analog taprostene to recombinant single-chain urokinase-type plasminogen activator in a canine coronary thrombosis model.

In open chest dogs myocardial ischemia was induced by formation of an occlusive thrombus in the left anterior circumflex artery (LCX). Reperfusion of the LCX was achieved by infusion of the fibrin specific recombinant single-chain urokinase-type plasminogen activator (r-scu-PA). The myocardial salvage by r-scu-PA alone and in combination with the epoprostenol (prostacyclin) analog taprostene (CG 4203) was compared.

Protection by recombinant human superoxide dismutase in lethal rat endotoxemia.

In summary as mechanism of the overall protective effect of r-HSOD in lethal rat endotoxemia, inhibition of hemoconcentration, a tendency of a decreased leukocyte activation and attenuation of consumption coagulopathy could be established.

Enhanced myocardial salvage by combined treatment with recombinant single-chain urokinase-type plasminogen activator and recombinant human superoxide dismutase in a canine coronary thrombosis model.

Myocardial ischemia was induced by formation of an occlusive thrombus in the left anterior circumflex artery (LCX) in open chest dogs. The myocardial salvage by the fibrin specific recombinant single-chain urokinase-type plasminogen activator (r-scu-PA) alone and in combination with the oxygen radical scavenger human superoxide dismutase of recombinant origin (r-HSOD) was investigated. The three experimental groups were: group I (n = 4) did not receive any treatment after LCX thrombosis; in group II (n = 9) at 100 min after LCX thrombosis r-scu-PA (20 micrograms.

Equieffective protection by human and bovine SOD against renal reperfusion damage in rats.

Both hum-SOD and bov-SOD improved the impaired renal function during kidney reperfusion. In the experiments with a 60-min occlusion period the effects of bov-SOD tended to be more pronounced than the effects of hum-SOD, whereas after a 30-min occlusion period the improvement of renal function by hum-SOD was more striking. In essence, therefore, hum-SOD proved to be equipotent to bov-SOD.